No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GMED240719C70000
- 1.10
- +0.19+20.88%
15min DelayClose Jul 11 16:00 ET
1.10High1.00Low
1.00Open0.91Pre Close11 Volume247 Open Interest70.00Strike Price1.15KTurnover25.10%IV0.49%PremiumJul 19, 2024Expiry Date0.75Intrinsic Value100Multiplier8DDays to Expiry0.35Extrinsic Value100Contract SizeAmericanOptions Type0.6304Delta0.1416Gamma46.39Leverage Ratio-0.0692Theta0.0097Rho29.25Eff Leverage0.0401Vega
Intraday
- 5D
- Daily
News
Here's Why Globus Medical (GMED) Is a Strong Value Stock
BTIG Maintains Globus Medical(GMED.US) With Buy Rating, Maintains Target Price $72
BTIG analyst Ryan Zimmerman maintains $Globus Medical(GMED.US)$ with a buy rating, and maintains the target price at $72.According to TipRanks data, the analyst has a success rate of 46.3% and a total
FDA Clears Orthopedics Robot From Globus Medical
Express News | Globus Medical Inc : RBC Raises Target Price to $76 From $70
RBC Raises Price Target on Globus Medical to $76 From $70, Maintains Outperform Rating
Globus Medical (GMED) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $55 to $85. Price: 66.80, Change: -0.20, Percent Change: -0.30
Globus Medical, Inc.'s (NYSE:GMED) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Globus Medical's (NYSE:GMED) stock is up by a considerable 29% over the past three months. However, we wonder if the company's inconsistent financials would have any adverse impact on the current sh
Comments
The company's CEO, Dan Scavilla, expressed confidence in Pfeil's ability to drive operational efficiency and deliver profitable growth, especially in light of the ongoing integration following their merger with NuVasive.
Press Release: Globus Medical Promotes Keith Pfeil to Chief Operating Officer and Chief Financial OfficerGlobus Medical's superior earnings outlook is contributing to its high P/E, which shareholders are currently comfortable with, expecting not to face a threat to future earnings. The confidence in the future earnings performance supports the current share price.
Globus Medical's persisting issues impact its valuation and a drop in EPS may spark shareholder worry. The long-term share performance is lackluster, unsettling even potential contrarian investors seeking a turnaround.
Read more